Literature DB >> 1913509

The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.

G M Higa1, J P Gockerman, A L Hunt, M R Jones, B J Horne.   

Abstract

An ocular toxic reaction presenting as conjunctivitis or keratitis develops in a significant number of patients who are treated with high-dose cytosine arabinoside (ara-C). Although eye drops containing glucocorticoid reportedly decrease the incidence, they do not totally eliminate this side effect. In comparing this technique with artificial tears, both were found to be equally effective. The primary mechanism by which eye drops decrease ocular toxic reactions associated with high-dose ara-C is presumably due to dilution of intraocular concentrations of ara-C.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1913509     DOI: 10.1002/1097-0142(19911015)68:8<1691::aid-cncr2820680805>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Bilateral corneal infections associated with topical steroid therapy prophylaxis for cytarabine arabinoside-induced keratoconjunctivitis.

Authors:  C Samarawickrama; A S Ioannidis; A W Wechsler; S L Watson
Journal:  Leukemia       Date:  2013-08-13       Impact factor: 11.528

2.  Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Yusuke Kawata; Mayu Ichimura; Chiaki Tsuneyama; Tomoko Yashima; Yoko Ogawa; Kazuo Tsubota; Naoyuki Shigematsu; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-08-19       Impact factor: 2.490

3.  Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis.

Authors:  A K Patel; W Sheehan; A Jenkins; C Lane; J Kell
Journal:  Int Ophthalmol       Date:  2011-03-18       Impact factor: 2.031

Review 4.  Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and Management.

Authors:  Shilpa Paul; Nicholas J Short
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

5.  Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Authors:  Gökçen Özcan; Ömür Özlenen Uçakhan
Journal:  Turk J Ophthalmol       Date:  2021-04-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.